Free Newsletter
ALSO NOTED: Teva's Accupril gets FDA OK; Elder Pharmaceuticals buys Biomeda;
> Teva has nabbed an OK from the FDA for its generic form of Accupril, Pfizer's high blood pressure remedy. Total U.S. sales of the drug--branded and generic forms--amounted to $150 million for the 12 months ended June 30. Release
> Indian drug maker Elder Pharmaceuticals has agreed to buy Bulgaria's Biomeda Group for €10 million in cash. It's Elder's second acquisition in two months; the company hopes to use Biomeda as leverage for more European product launches. Report
> Medical laser-maker Candela got a new indication from the FDA for its Serenity device, used to reduce pain during pulsed-light and laser treatments. Report
And Finally... Low-dose products for menopause treatment have flooded the market with since the Women's Health Initiative found that hormone therapy could be harmful. But there's no research proving low doses are safer than traditional products. Article
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





